Pyrazolopyrimidine compounds

Abstract

The present teachings provide a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

1 . A compound represented by the following structural formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         R 1  is —NH—CH 2 —Cy, 
         Cy is C 3 -C 4  cycloalkyl optionally substituted with one or two groups selected from alkyl and hydroxyl; 
         R 2  is —NH—(C 2 -C 6 )hydroxyalkyl optionally substituted with cyclopropyl or isopropyl; or —NH—(C 3 -C 6 )cycloalkyl optionally substituted with hydroxyl or (C 1 -C 2 )hydroxylalkyl; 
         R 4  is selected from hydrogen, halogen, and (C 1 -C 3 )alkyl; and 
         R d  is cyclopropyl. 
       
     
     
         2 - 6 . (canceled) 
     
     
         7 . A pharmaceutical composition comprising a compound of  claim 1  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. 
     
     
         8 . A method for treating cancer, the method comprising administering to a subject in need thereof an effective amount of the compound of  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method of  claim 8 , wherein the cancer is pancreatic cancer, prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, or ovarian cancer.